Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

32
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
32
Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

33
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
33
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

46
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
46
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

33
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
33
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

90
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
90
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

600
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
600

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

White matter abnormalities in Alzheimer's disease: Implications for pathophysiology, diagnosis, and treatment.

Ageing research reviews·2026
Same author

A 57-Year-Old Male With Behavioral Variant Frontotemporal Dementia and MATR3 and NOS3 Mutations.

Annals of clinical and translational neurology·2026
Same author

High-Conductivity Flexible MXene Electromagnetic Films for Radio-Frequency Antennas.

Nano letters·2026
Same author

Single-Section Sequential MALDI-MSI Reveals Metabolic and N-Glycan Remodeling During Malignant Transformation in Hepatocellular Adenoma.

Metabolites·2026
Same author

Design and Discovery of Pyridazinone-Based MAT2A Inhibitors Targeting MTAP-Deficient Cancers.

Journal of medicinal chemistry·2026
Same author

A Depth-Controlled Longitudinal Cutting Strategy Enhances MALDI-MSI of Entire Leaves.

Analytical chemistry·2026

Related Experiment Video

Updated: Jun 9, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.4K

Predicting Food-Drug Interactions between Piperine and CYP3A4 Substrate Drugs Using PBPK Modeling.

Feifei Lin1,2, Yingchun Hu2, Yifan Zhang2

  • 1School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310058, China.

International Journal of Molecular Sciences
|October 26, 2024
PubMed
Summary
This summary is machine-generated.

Piperine, found in black pepper, can significantly increase levels of certain medications metabolized by cytochrome P450 3A4. This suggests potential drug interactions when consuming piperine with these common drugs.

Keywords:
CYP3A4PBPK modelingfood–drug interactionpiperine

More Related Videos

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

1.9K
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

7.8K

Related Experiment Videos

Last Updated: Jun 9, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.4K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

1.9K
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

7.8K

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Pharmacokinetics

Background:

  • Piperine is known to inhibit cytochrome P450 (CYP) 3A4 enzyme activity.
  • Understanding these interactions is crucial for patient safety and effective drug therapy.

Purpose of the Study:

  • To develop and validate a physiologically based pharmacokinetic (PBPK) model for piperine.
  • To predict potential food-drug interactions (FDIs) between piperine and CYP3A4 substrate drugs.

Main Methods:

  • Development and validation of a PBPK model for piperine.
  • Simulation of FDIs between piperine and ten CYP3A4 substrate drugs.

Main Results:

  • The PBPK model for piperine was successfully developed and validated.
  • Simulations predicted significant increases in the area under the curve (AUC) for six CYP3A4 substrates, including ritonavir, nifedipine, cyclosporine, triazolam, alfentanil, and simvastatin, with daily piperine intake.
  • Predicted AUC ratios exceeded 1.25 for these drugs, indicating substantial pharmacokinetic alterations.

Conclusions:

  • Caution is advised when consuming black pepper (equivalent to 20 mg piperine daily) concurrently with CYP3A4 substrate drugs.
  • Piperine may significantly alter the pharmacokinetics of commonly prescribed medications metabolized by CYP3A4.